Phuturdex › Diseases › COVID-19
Drugs in development · updated 30 October 2026
COVID-19: drugs in development
As of 30 October 2026 there are 66 active clinical trials (recruiting or ongoing, phases I–III) on 104 drugs for COVID-19. 48 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MolnupiravirLagevrio® | III | 4 | NCT06667700 |
| SotrovimabVIR-7831, Xevudy® | III | 3 | NCT04381936 |
| Ibuzatrelvir | III | 2 | NCT06679140 |
| Secutrelvir | III | 2 | NCT07743580 |
| AzeliragonTTP488 | II–III | 1 | NCT05815485 |
| DAS181 | III | 1 | NCT03808922 |
| DMX-200 | III | 1 | NCT02735707 |
| Eritoran | III | 1 | NCT02735707 |
| Novavax | III | 1 | NCT05658523 |
| Riltozinameran | III | 1 | NCT05993325 |
| SCTA01 | II–III | 1 | NCT04709328 |
| Tozorakimab | III | 1 | NCT05624450 |
| VYD2311-MD | III | 1 | NCT07298434 |
| VYD2311-SD | III | 1 | NCT07298434 |
| COVID-19 | II | 3 | NCT06599658 |
| Favipiravir | I–II | 2 | NCT04746183 |
| VYD2311 | II | 2 | NCT07899346 |
| [18F]F-AraG[18F]-AraG | II | 1 | NCT04815096 |
| AER002 | II | 1 | NCT05877508 |
| ALG-097558 | I–II | 1 | NCT04746183 |
| AtibuclimabIC14 | II | 1 | NCT04488081 |
| Atilotrelvir | II | 1 | NCT05041907 |
| Aviptadil | II | 1 | NCT04488081 |
| BEZ235RTB101 | II | 1 | NCT04584710 |
| Cenicriviroc | II | 1 | NCT04488081 |
| Citicoline | I–II | 1 | NCT05881135 |
| Clazakizumab | II | 1 | NCT04494724 |
| Cormirnaty | I–II | 1 | NCT06821126 |
| Covifenz | II | 1 | NCT04894435 |
| Ebselen | II | 1 | NCT04484025 |
| Efesovir | II | 1 | NCT05060705 |
| Fisetin | II | 1 | NCT04476953 |
| LVT-001 | I–II | 1 | NCT06821126 |
| MRNA-1273 | II | 1 | NCT07808697 |
| MRNA-1283 | II | 1 | NCT07808697 |
| Optate | II | 1 | NCT05799521 |
| Ratutrelvir | II | 1 | NCT07157007 |
| Tianeptine | II | 1 | NCT06012552 |
| VIR-7832 | I–II | 1 | NCT04746183 |
| AVM0703 | I | 1 | NCT04366115 |
Sorted by most advanced phase and number of active trials. Showing 40 of 48 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RemdesivirVeklury | III | 7 | NCT07013474 |
| Paxlovid | III | 6 | NCT04381936 |
| Nirmatrelvir | III | 4 | NCT05852873 |
| RitonavirNorvir®, Ritonavir Viatris (previously Ritonavir Mylan)® | III | 4 | NCT05852873 |
| AnakinraKINERET | II–III | 3 | NCT05926505 |
| BaricitinibOlumiant® | III | 3 | NCT06631287 |
| HydroxychloroquineSovuna®, Plaquenil® | III | 3 | NCT04381936 |
| NitazoxanideAlinia® | III | 3 | NCT06817096 |
| ApremilastOtezla, Apremilast Accord® | III | 2 | NCT02735707 |
| AspirinVazalore®, Durlaza® | III | 2 | NCT04381936 |
| Baloxavir MarboxilXofluza® | III | 2 | NCT04381936 |
| ImatinibSTI571, Imkeldi® | III | 2 | NCT02735707 |
| IvermectinSoolantra®, Sklice® | III | 2 | NCT02735707 |
| OseltamivirTamiflu®, Ebilfumin® | III | 2 | NCT04381936 |
| TocilizumabTociluzumab, Avtozma | III | 2 | NCT04381936 |
Sorted by most advanced phase and number of active trials. Showing 15 of 56 drugs.
All 104 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Post-Acute COVID-19 Syndrome 44 drugs
- Fatigue 24 drugs
- Myalgic encephalomyelitis/chronic fatigue syndrome 7 drugs
- Cognitive dysfunction 94 drugs
- Non-small-cell lung carcinoma 726 drugs
- Tinnitus 12 drugs
- Pulmonary fibrosis 34 drugs
- Ventricular remodeling 4 drugs
- Left ventricular dysfunction 10 drugs
- Microvascular angina 7 drugs
- Myocarditis 8 drugs
- Pericarditis 6 drugs
Broader categories
- Respiratory disease 57 drugs
- RNA virus infectious disease 8 drugs
- Infection 71 drugs
- Viral pneumonia 6 drugs
- Lung disease 104 drugs
- Pneumonia 63 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000086382 “COVID-19”.